Studies have demonstrated that knocking down IRF8 can alleviate behavioral deficits in MPTP-induced PD mouse models, increase the dopamine content, reduce inflammatory cytokine levels, and inhibit the activation of the AMPK/mTOR signaling pathway [81]. This evidence concerns the gene IRF8 and Parkinson disease.